SB 221420AAlternative Names: SB 221420
Latest Information Update: 16 Mar 2000
At a glance
- Originator GlaxoSmithKline
- Class Neuroprotectants
- Mechanism of Action Calcium channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neuroprotection
Most Recent Events
- 16 Mar 2000 New profile
- 16 Mar 2000 Discontinued-Preclinical for Neuroprotection in United Kingdom (Unknown route)